Belzutifan is a CYP2C19 substrate. Coadministration with CYP2C19 inhibitors may increase incidence or severity of adverse consequences. Monitor for anemia and hypoxia and decrease belzutifan dose as advisable. apalutamide will minimize the level or influence of modafinil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate https://andreerakt.iyublog.com/25890016/getting-my-modafinil-to-work